Phase I Trial Allocation Directed by Immunologically Classified Cancers Refractory to Anti-Pd-1 / Pd-L1 Antibodies

Project title

針對抗PD-1、PD-L1抗體治療失效的癌症以腫瘤免疫生物標記來分派癌症免疫治療第一期臨床試驗

Internal ID

MOST108-2314-B002-077

Principal Investigator

Start Date

August 1, 2019

End Date

July 31, 2020

Organizations

Clinical Medicine

Partner Organizations

National Science and Technology Council